Cristina Donini Selected Research

1-Phosphatidylinositol 4-Kinase (1 Phosphatidylinositol 4 Kinase)

12/2020	A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048.
1/2018	UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cristina Donini Research Topics

Disease

7	Malaria 01/2022 - 09/2015
4	Infections 01/2021 - 09/2015
1	Diaphragmatic Hernia 01/2022
1	Vivax Malaria 01/2020
1	Body Weight (Weight, Body) 09/2015
1	Lymphopenia (Lymphocytopenia) 03/2010

Drug/Important Bio-Agent (IBA)

5	MMV390048IBA 01/2022 - 01/2017
4	Pharmaceutical PreparationsIBA 01/2022 - 09/2015
4	Antimalarials (Antimalarial Agents)IBA 01/2021 - 01/2017
2	AminopyridinesIBA 01/2022 - 01/2022
2	1-Phosphatidylinositol 4-Kinase (1 Phosphatidylinositol 4 Kinase)IBA 12/2020 - 01/2018
2	alpha-aminopyridineIBA 01/2018 - 01/2017
1	Phosphotransferases (Kinase)IBA 01/2022
1	Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)IBA 01/2022
1	6- Chloro- 7- methoxy- 2- methyl- 3- (4- (4- (trifluoromethoxy)phenoxy)phenyl)quinolin- 4(1H)- oneIBA 09/2015
1	ProdrugsIBA 09/2015
1	Sphingosine-1-Phosphate ReceptorsIBA 03/2010

Therapy/Procedure

2	Therapeutics 01/2022 - 12/2020
1	Oral Administration 09/2015